{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=13", "query": { "intervention": "Combination Agent", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 5568, "total_pages": 557, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T11:31:55.275Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02421120", "title": "Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cystic Fibrosis", "Cystic Fibrosis Pulmonary Exacerbation", "Pseudomonas Aeruginosa Infection" ], "interventions": [ { "name": "Ceftolozane/Tazobactam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joseph L. Kuti, PharmD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2015-09", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2020-08-04", "last_synced_at": "2026-11-15T11:31:55.275Z", "location_count": 4, "location_summary": "Hartford, Connecticut • Indianapolis, Indiana • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02421120" }, { "nct_id": "NCT03451110", "title": "Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "lemborexant", "type": "DRUG" }, { "name": "Loestrin", "type": "DRUG" }, { "name": "famotidine", "type": "DRUG" }, { "name": "fluconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 50, "start_date": "2018-02-05", "completion_date": "2018-03-23", "has_results": false, "last_update_posted_date": "2018-09-06", "last_synced_at": "2026-11-15T11:31:55.275Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03451110" }, { "nct_id": "NCT00593060", "title": "Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey W. Clark, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2007-11-01", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2023-05-24", "last_synced_at": "2026-11-15T11:31:55.275Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00593060" }, { "nct_id": "NCT00013520", "title": "Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Abacavir sulfate, Lamivudine and Zidovudine", "type": "DRUG" }, { "name": "Atazanavir", "type": "DRUG" }, { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Nevirapine", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 1125, "start_date": null, "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2012-05-21", "last_synced_at": "2026-11-15T11:31:55.275Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00013520" }, { "nct_id": "NCT03153410", "title": "Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GVAX Pancreas Vaccine (GVAX)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "IMC-CS4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2018-09-27", "completion_date": "2023-08-29", "has_results": true, "last_update_posted_date": "2025-01-09", "last_synced_at": "2026-11-15T11:31:55.275Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03153410" }, { "nct_id": "NCT04982224", "title": "Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced NSCLC" ], "interventions": [ { "name": "REGN5093-M114", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-11-09", "completion_date": "2025-10-15", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-11-15T11:31:55.275Z", "location_count": 11, "location_summary": "Orange, California • Denver, Colorado • Baltimore, Maryland + 7 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04982224" }, { "nct_id": "NCT05091346", "title": "A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Carcinoma, Hepatocellular", "Colorectal Neoplasms" ], "interventions": [ { "name": "E7386", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2021-10-27", "completion_date": "2024-10-15", "has_results": true, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-11-15T11:31:55.275Z", "location_count": 10, "location_summary": "Los Angeles, California • Orange, California • Fort Myers, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05091346" }, { "nct_id": "NCT01070888", "title": "Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Exercise Induced Asthma" ], "interventions": [ { "name": "Budesonide/Formoterol", "type": "DRUG" }, { "name": "Budesonide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "12 Years to 50 Years" }, "enrollment_count": 6, "start_date": "2010-02", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2021-07-07", "last_synced_at": "2026-11-15T11:31:55.275Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01070888" }, { "nct_id": "NCT03078010", "title": "Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intestinal Microbiome", "Febrile Neutropenia" ], "interventions": [ { "name": "Piperacillin-tazobactam", "type": "DRUG" }, { "name": "cefepime", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 347, "start_date": "2017-02-10", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-11-15T11:31:55.275Z", "location_count": 2, "location_summary": "Hackensack, New Jersey • New York, New York", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03078010" }, { "nct_id": "NCT04677959", "title": "A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone propionate/salmeterol (FS)", "type": "DRUG" }, { "name": "Albuterol", "type": "DRUG" }, { "name": "Standard of Care Asthma Medication", "type": "DRUG" }, { "name": "Standard of Care Rescue Medication", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 427, "start_date": "2021-02-16", "completion_date": "2022-03-10", "has_results": true, "last_update_posted_date": "2023-03-14", "last_synced_at": "2026-11-15T11:31:55.275Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04677959" } ] }